News

BREAKWATER Expands First-Line Treatment Options for Patients With BRAF V600E–Mutant Metastatic Colorectal Cancer

05/31/2026

Stephanie Holland

First-line encorafenib, cetuximab, and FOLFIRI significantly improved response rates and PFS and prolonged OS vs FOLFIRI ± bevacizumab in patients with BRAF V600E–mutant metastatic colorectal cancer, according to findings from cohort 3 of the...

First-line encorafenib,...

05/31/2026

Oncology

News

Trastuzumab Rezetecan Shows Strong Clinical Promise in HER2-Positive Advanced Colorectal Cancer

05/27/2026

Emily Estrada

According to results from a phase 3 trial, trastuzumab rezetecan significantly improved survival and response in chemotherapy-refractory HER2-positive advanced colorectal cancer.

According to results from a...

05/27/2026

Oncology

News

Trastuzumab Rezetecan Shows Strong Clinical Promise in HER2-Positive Advanced Colorectal Cancer

05/27/2026

Emily Estrada

According to results from a phase 3 trial, trastuzumab rezetecan significantly improved survival and response in chemotherapy-refractory HER2-positive advanced colorectal cancer.

According to results from a...

05/27/2026

Oncology

News

Postsurgical ctDNA is Associated With Recurrence in Metastatic Colorectal Cancer

05/19/2026

Emily Estrada

Results from a prospective study suggest that ctDNA dynamics may help stratify recurrence risk in patients with liver-limited metastatic colorectal cancer undergoing liver resection after upfront chemotherapy.

Results from a prospective study...

05/19/2026

Oncology

News

Glecirasib-Based Regimens Show Promise in KRAS G12C-Mutant Metastatic Colorectal Cancer

05/07/2026

Emily Estrada

Combined results from the JAB-21822-1002 and JAB-21822-1007 trials demonstrate that glecirasib shows clinical promise both alone and in combination with cetuximab in KRAS G12C-mutated locally advanced or metastatic colorectal cancer.

Combined results from the...

05/07/2026

Oncology

News

ctDNA Dynamics to Predict Survival Outcomes in Patients With Metastatic Colorectal Cancer

05/07/2026

Emily Estrada

Exploratory ctDNA results from the phase 2 VALENTINO study demonstrated that baseline detection and early ctDNA dynamics are strongly associated with clinical outcomes in patients with metastatic colorectal cancer.

Exploratory ctDNA results from...

05/07/2026

Oncology

News

Etrumadenant-Based Chemoimmunotherapy Improves Survival in Metastatic Colorectal Cancer

04/01/2026

Emily Estrada

Results from the phase 2 ARC-9 study, demonstrate that etrumadenant plus zimberelimab, mFOLFOX-6, and bevacizumab significantly improves survival in heavily pretreated patients with metastatic colorectal cancer.

Results from the phase 2 ARC-9...

04/01/2026

Oncology

News

Botensilimab Plus Balstilimab Demonstrates Promise in Refractory Metastatic Colorectal Cancer

03/18/2026

Emily Estrada

According to a comparative analysis of clinical trial data, botensilimab plus balstilimab provided a promising overall survival benefit in refractory MSS metastatic colorectal cancer.

According to a comparative...

03/18/2026

Oncology

News

Zanzalintinib Plus Atezolizumab Significantly Improves OS in Relapsed or Refractory Metastatic Colorectal Cancer

02/06/2026

Stephanie Holland

Results from the STELLAR-303 trial demonstrate that zanzalintinib plus atezolizumab significantly improves overall survival compared with regorafenib in relapsed or refractory metastatic colorectal cancer without MSI-H or dMMR tumors.

Results from the STELLAR-303...

02/06/2026

Oncology

News

Tucatinib Plus Trastuzumab Shows Durable Efficacy and Manageable Safety for HER2-Posititive Metastatic Colorectal Cancer

01/27/2026

Emily Estrada

Tucatinib plus trastuzumab provided durable responses and a favorable safety profile among patients with chemotherapy-refractory, HER2positive metastatic colorectal cancer, based on results from the phase 2 MOUNTAINEER trial.

Tucatinib plus trastuzumab...

01/27/2026

Oncology

Recent News

News

Camrelizumab Plus Apatinib Demonstrates Encoruaging Activity in Patients With Refractory Chordoma

06/26/2026

Emily Estrada

According to results from an investigator-initiated phase 2 study, camrelizumab plus apatinib demonstrated encouraging efficacy and durable disease control in patients with refractory chordoma.

According to results from an...

06/26/2026

Oncology

News

Ten-Year Follow-Up Supports Curative Potential of Tisagenlecleucel in Patients With B-Cell Non-Hodgkin Lymphomas

06/25/2026

Stephanie Holland

Long-term follow-up of patients with relapsed or refractory B-cell non-Hodgkin lymphoma demonstrated that tisagenlecleucel induced durable remissions, with no disease relapses occurring beyond 5.4 years after treatment.

Long-term follow-up of patients...

06/25/2026

Oncology

News

Pirtobrutinib Demonstrates Durable Clinical Activity in Relapsed or Refractory Waldenström Macroglobulinemia

06/25/2026

Stephanie Holland

Results from the phase 1/2 BRUIN trial demonstrated that pirtobrutinib shows durable clinical activity in relapsed or refractory Waldenström macroglobulinemia, including those previously treated with covalent Bruton tyrosine kinase inhibitors.

Results from the phase 1/2 BRUIN...

06/25/2026

Oncology

News

Nivolumab Plus Ipilimumab Shows Encouraging Activity in Advanced Gallbladder Carcinoma

06/25/2026

Stephanie Holland

According to results from the phase 2 MoST-CIRCUIT trial, nivolumab plus ipilimumab demonstrated encouraging activity in patients with gallbladder carcinoma despite limited overall efficacy in patients with advanced biliary tract cancers.

According to results from the...

06/25/2026

Oncology

News

Neoadjuvant Nivolumab Demonstrates Strong Activity in Resectable Mismatch Repair-Deficient Endometrial Cancer

06/23/2026

Emily Estrada

Results from a phase 2 study demonstrated that neoadjuvant nivolumab induced high rates of complete response among patients with resectable mismatch repair-deficient endometrial cancer.

Results from a phase 2 study...

06/23/2026

Oncology

News

Bulumtatug Fuvedotin Demonstrates Durable Activity in Previously Treated Cervical Cancer

06/23/2026

Emily Estrada

Updated results from a phase 2 study demonstrated that bulumtatug fuvedotin shows encouraging efficacy and manageable tolerability in patients with recurrent or metastatic cervical cancer, including those previously treated with immune...

Updated results from a phase 2...

06/23/2026

Oncology

FDA Approval

FDA Approves Afamitresgene Autoleucel for Patients With Unresectable or Metastatic Synovial Sarcoma

06/23/2026

Stephanie Holland

Based on results from the SPEARHEAD-1 study, the FDA granted full approval to afamitresgene autoleucel for unresectable or metastatic synovial sarcoma and expanded its indication to include eligible patients aged 12 years and older.

Based on results from the...

06/23/2026

Oncology

News

Signatera-Based ctDNA Testing Incorporated Into NCCN Bladder Cancer Guidelines

06/23/2026

Stephanie Holland

The NCCN has updated its Clinical Practice Guidelines in Oncology for Bladder Cancer to include tumor-informed ctDNA-MRD testing as a tool for risk stratification and treatment selection in patients with muscle-invasive bladder cancer.

The NCCN has updated its...

06/23/2026

Oncology

News

Dostarlimab Demonstrates Durable 6-Year Survival Benefit in dMMR/MSI-H Endometrial Cancer

06/18/2026

Stephanie Holland

Updated results from the phase 1 GARNET trial demonstrated durable long-term clinical benefit with dostarlimab monotherapy in patients with dMMR/MSI-H advanced or recurrent endometrial cancer.

Updated results from the phase 1...

06/18/2026

Oncology

News

Updated Results from the RUBY Trial Reinforce Dostarlimab as Standard of Care in dMMR/MSI-H Endometrial Cancer

06/18/2026

Stephanie Holland

Updated results from the phase 3 RUBY trial demonstrated that dostarlimab plus carboplatin and paclitaxel sustained survival benefit in patients with dMMR/MSI-H primary advanced or recurrent endometrial cancer.

Updated results from the phase 3...

06/18/2026

Oncology